Giampaolo Tortora

Giampaolo Tortora's AcademicInfluence.com Rankings

Giampaolo Tortora

Computer Science

#4599

World Rank

#4852

Historical Rank

Machine Learning

#954

World Rank

#968

Historical Rank

Artificial Intelligence

#1173

World Rank

#1194

Historical Rank

Database

#1810

World Rank

#1898

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Giampaolo Tortora's Degrees

PhD Computer Science University of Milan
Bachelors Computer Science University of Milan

Similar Degrees You Can Earn

Why Is Giampaolo Tortora Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giampaolo Tortora's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genomic analyses identify molecular subtypes of pancreatic cancer (2016) (2343)
Whole genomes redefine the mutational landscape of pancreatic cancer (2015) (1983)
EGFR antagonists in cancer treatment. (2008) (1911)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) (1752)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (2019) (1152)
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001) (1008)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. (2000) (989)
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. (2001) (654)
Whole-genome landscape of pancreatic neuroendocrine tumours (2017) (616)
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002) (611)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas (2013) (555)
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy (2018) (529)
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. (2002) (459)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers (2015) (408)
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. (2000) (395)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy (2004) (343)
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. (1999) (339)
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. (2003) (330)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. (2007) (325)
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. (1998) (319)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018) (296)
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis (2008) (294)
A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer (2005) (288)
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). (2002) (265)
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015) (243)
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. (2003) (238)
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. (2012) (233)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups (2014) (161)
Hypermutation In Pancreatic Cancer. (2017) (160)
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D (2016) (160)
Metabolic phenotype of bladder cancer. (2016) (158)
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. (2015) (157)
Key cancer cell signal transduction pathways as therapeutic targets. (2006) (156)
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. (1996) (150)
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. (2003) (149)
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells (2008) (141)
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. (2000) (136)
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs (2008) (136)
Rational bases for the development of EGFR inhibitors for cancer treatment. (2007) (133)
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. (2005) (129)
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. (2006) (117)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial (2017) (116)
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications (2008) (115)
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (2019) (115)
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer (2018) (113)
Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogues. (1988) (111)
Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues (1996) (110)
Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. (1991) (110)
The role of EGFR inhibitors in nonsmall cell lung cancer (2004) (109)
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma (2013) (107)
Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel (2013) (105)
The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-Receptor (1997) (105)
Anti-epidermal growth factor receptor drugs in cancer therapy (2002) (104)
Gut microbiome, big data and machine learning to promote precision medicine for cancer (2020) (102)
Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy (2002) (99)
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program (2019) (98)
Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation. (1989) (98)
An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. (1993) (96)
ZD1839 (IRESSA), an EGFR‐selective tyrosine kinase inhibitor, enhances taxane activity in bcl‐2 overexpressing, multidrug‐resistant MCF‐7 ADR human breast cancer cells (2002) (94)
Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. (1998) (93)
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. (2005) (92)
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer (2017) (90)
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines (2001) (89)
Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma (2005) (84)
Chemotherapy in metastatic renal cell carcinoma today? A systematic review (2013) (83)
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy (2013) (83)
Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate. (1989) (83)
Angiogenesis: a target for cancer therapy. (2004) (83)
An antisense oligodeoxynucleotide targeted against the type II beta regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. (1990) (81)
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer (2006) (81)
Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. (1988) (79)
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. (1998) (78)
Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors (2006) (77)
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. (2007) (77)
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. (2003) (76)
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. (2010) (76)
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. (2007) (75)
8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. (2000) (70)
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. (1990) (70)
Role of site-selective cAMP analogs in the control and reversal of malignancy. (1991) (69)
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. (2007) (69)
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. (2008) (68)
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. (1999) (68)
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing (2016) (67)
A novel MDM2 anti‐sense oligonucleotide has anti‐tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer (2000) (67)
Metabolic alterations in renal cell carcinoma. (2015) (67)
Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. (2019) (66)
The RIalfa subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. (1994) (66)
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts (2007) (65)
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. (2017) (64)
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? (2015) (63)
Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. (2019) (63)
Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. (1994) (63)
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around (2019) (62)
Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. (2003) (62)
Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines. (1988) (60)
Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases (2006) (60)
Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. (1996) (60)
Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer (2006) (58)
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis (2016) (58)
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. (2012) (58)
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients (2016) (57)
Antitumor Effects of ZD 6474 , a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor , with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase 1 (2003) (57)
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). (2011) (57)
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma (2020) (57)
Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. (2000) (56)
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. (2015) (56)
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. (2004) (56)
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma (2015) (56)
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. (2011) (54)
Emerging pathways and future targets for the molecular therapy of pancreatic cancer (2011) (54)
Do immune checkpoint inhibitors need new studies methodology? (2018) (54)
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. (1997) (54)
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? (2016) (54)
Resistance to taxanes is induced by c‐erbB‐2 overexpression in human MCF‐10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A (2000) (54)
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. (2015) (53)
The prospect of precision therapy for renal cell carcinoma. (2016) (52)
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. (2003) (52)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. (2019) (52)
Role of STAT3 pathway in genitourinary tumors (2015) (52)
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. (2021) (52)
Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer (2002) (52)
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers (2013) (52)
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? (2018) (52)
AR-V7 and prostate cancer: The watershed for treatment selection? (2016) (52)
Treatment‐related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up‐to‐date review and meta‐analysis of clinical trials (2015) (49)
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung (2014) (49)
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. (2001) (49)
Exome sequencing identifies frequent inactivating mutations in BAP 1 , ARID 1 A and PBRM 1 in intrahepatic cholangiocarcinomas (2014) (49)
Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers (2011) (49)
Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells. (1989) (49)
Down‐regulation of riα subunit of camp‐dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c‐ha‐ras and c‐erbb‐2 proto‐oncogenes (1993) (48)
CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors (2014) (47)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. (2000) (47)
Pembrolizumab as first-line treatment for metastatic uveal melanoma (2019) (47)
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer (2015) (47)
Unhydrolyzable analogues of adenosine 3':5'-monophosphate demonstrating growth inhibition and differentiation in human cancer cells. (1992) (46)
Chemosensitization by antisense oligonucleotides targeting MDM2. (2005) (45)
New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors (2016) (45)
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. (1997) (45)
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. (1997) (44)
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis (2014) (44)
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. (2016) (44)
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer (2015) (44)
Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer (2004) (44)
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. (2005) (41)
Sex differences in oncogenic mutational processes (2019) (41)
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. (2017) (41)
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives (2020) (41)
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma (2012) (40)
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. (2004) (40)
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. (2020) (40)
Type II regulatory subunit of protein kinase restores cAMP-dependent transcription in a cAMP-unresponsive cell line. (1990) (40)
PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target (2019) (39)
Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis (2014) (39)
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors (2020) (39)
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex (2018) (38)
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies (2015) (38)
The obesity paradox in cancer: clinical insights and perspectives (2018) (38)
Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation (2012) (38)
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. (2005) (37)
Monoclonal antibodies targeting the epidermal growth factor receptor. (2005) (37)
Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications. (2000) (37)
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer (2020) (37)
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. (2018) (37)
Antisense strategies targeting protein kinase C: preclinical and clinical development. (2003) (36)
Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials. (2020) (36)
Profiling mTOR pathway in neuroendocrine tumors (2012) (36)
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action (2009) (36)
High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs (2014) (36)
Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer (2012) (36)
Expression of Wnt5a is downregulated by extracellular matrix and mutated c-Ha-ras in the human mammary epithelial cell line MCF-10A. (1997) (35)
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs (2012) (35)
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours (2010) (35)
Inhibition of bcl-2 as cancer therapy. (2002) (34)
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma (2018) (34)
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations (2018) (34)
Suppression of malignancy targeting the intracellular signal transducing proteins of cAMP: the use of site-selective cAMP analogs, antisense strategy, and gene transfer. (1991) (34)
Skin cancer triage and management during COVID‐19 pandemic (2020) (34)
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). (2016) (34)
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors (2020) (34)
Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease (2005) (33)
Pancreatic cancer: systemic combination therapies for a heterogeneous disease. (2014) (33)
Infection with a transforming growth factor α anti‐sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line (1993) (33)
Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence. (2020) (32)
Rationale and clinical use of multitargeting anticancer agents. (2013) (32)
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients (2017) (32)
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. (2018) (32)
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer (2019) (31)
Genitourinary tumors, non-prostate (2012) (31)
Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. (2001) (31)
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. (2016) (31)
Mechanisms of resistance to HER2 target therapy. (2011) (31)
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage (2017) (31)
Clinical Studies in Patients with Solid Tumors using a Second‐Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I (2003) (31)
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research (2011) (30)
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma (2017) (30)
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. (2018) (30)
Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate. (1992) (30)
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement (2012) (30)
Amphiregulin anti‐sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line (1995) (29)
Differential effects of protein kinase a sub‐units on chinese‐hamster‐ovary cell cycle and proliferation (1994) (29)
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go (2021) (29)
Retroviral vector-mediated overexpression of the RII beta subunit of the cAMP-dependent protein kinase induces differentiation in human leukemia cells and reverts the transformed phenotype of mouse fibroblasts. (1994) (29)
Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions (2017) (29)
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer (2014) (29)
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients (2015) (28)
Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cyclic AMP-dependent protein kinase. (1993) (28)
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials (2003) (28)
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside (2014) (28)
Targeting the epidermal growth factor receptor in solid tumors: focus on safety (2014) (28)
Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. (2014) (28)
Combined inhibition of IL1, CXCR1/2, and TGF&bgr; signaling pathways modulates in-vivo resistance to anti-VEGF treatment (2016) (28)
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. (2017) (28)
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. (2017) (28)
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy? (2019) (28)
Safety and Efficacy of Cabozantinib in Metastatic Renal‐Cell Carcinoma: Real‐World Data From an Italian Managed Access Program (2018) (28)
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. (2022) (27)
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? (2018) (27)
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance (2018) (27)
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. (2015) (26)
Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death* (2009) (26)
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. (2007) (26)
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody (2013) (26)
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. (2007) (26)
The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer (2019) (26)
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. (1999) (25)
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story (2019) (25)
Toll-Like Receptor 9 Agonists for Cancer Therapy (2014) (25)
Gefitinib Induction of In vivo Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3 (2008) (25)
Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma (2019) (25)
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder (2015) (25)
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. (2014) (25)
Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy (2003) (25)
Transfection with a CRIPTO anti‐sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line (1996) (25)
Tp53 and its potential therapeutic role as a target in bladder cancer (2017) (24)
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion (2021) (24)
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy (2018) (24)
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. (2013) (24)
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice (2016) (24)
Molecular targets on the horizon for kidney and urothelial cancer (2013) (23)
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. (2015) (23)
EGFR-targeting agents in oncology (2008) (23)
Mechanisms of resistance to EGFR inhibitors (2007) (23)
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma (2019) (22)
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer (2013) (22)
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. (2004) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment (2020) (21)
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib (2019) (21)
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system (2017) (21)
The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. (1994) (21)
Effect of thymic extract 'thymostimulin' on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. (1988) (21)
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis (2020) (21)
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials. (2015) (21)
Tubulin inhibitors in non-small cell lung cancer: looking back and forward (2016) (20)
Strategies for Multiple Signalling Inhibition (2004) (20)
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. (2015) (20)
Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review (2021) (20)
Cooperative effect of 8-Cl-cAMP and rhGM-CSF on the differentiation of HL-60 human leukemia cells. (1991) (20)
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease (2019) (20)
The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome (2018) (19)
Prognostication and response assessment in liver and pancreatic tumors: The new imaging. (2015) (19)
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer (2018) (19)
Effects of 8-chloroadenosine 3',5'-monophosphate and N6-benzyl-cyclic adenosine 5'-monophosphate on cell cycle kinetics of HL-60 leukemia cells. (1991) (19)
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? (2015) (18)
[New frontiers in cancer treatment]. (2006) (18)
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs (2008) (18)
Protein kinase A type I: a target for cancer therapy. (2002) (18)
Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay (2018) (18)
Site‐selective 8‐C1‐cAMP which causes growth inhibition and differentiation increases DNA (CRE)‐binding activity in cancer cells (1989) (18)
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors (2015) (18)
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer (2016) (18)
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis (2016) (18)
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges (2020) (18)
Flow-cytometric detection of the RI alpha subunit of type I cAMP-dependent protein kinase in human cells. (1994) (18)
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer (2021) (17)
The route to personalized medicine in bladder cancer: where do we stand? (2015) (17)
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2022) (17)
Bladder cancer: molecular determinants of personalized therapy. (2015) (17)
The development of PARP as a successful target for cancer therapy (2018) (17)
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. (2018) (17)
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach (2016) (17)
POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm). (2016) (17)
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. (2006) (17)
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. (2014) (16)
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. (2019) (16)
Metabolic Alterations in Renal and Prostate Cancer. (2016) (16)
Efficacy of immune checkpoint inhibitors in different types of melanoma (2020) (16)
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer (2021) (16)
Reduction of RIα Subunit of cAMP‐dependent Protein Kinase Expression Induces Growth Inhibition of Human Mammary Epithelial Cells Transformed by TGF‐α, c‐Ha‐ras, and c‐erbB‐2 Genes (1993) (15)
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. (2013) (15)
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. (2017) (15)
Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature (2018) (15)
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now! (2021) (15)
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis (2013) (15)
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. (1999) (15)
Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians (2020) (15)
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? (2015) (14)
Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities (2021) (14)
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. (2017) (14)
Adenocarcinoma of the paraurethral glands: a case report. (2014) (14)
Muscle derangement and alteration of the nutritional machinery in NSCLC. (2019) (14)
Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR (2012) (14)
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study (2020) (14)
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies (2018) (13)
Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. (2014) (13)
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives (2015) (13)
Structure-activity relationship, physicochemical and pharmacokinetic properties of AZD2171: A highly potent inhibitor of VEGF receptor tyrosine kinases (2004) (13)
In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches (2007) (13)
Cabozantinib‐related cardiotoxicity: a prospective analysis in a real‐world cohort of metastatic renal cell carcinoma patients (2019) (13)
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents. (2015) (13)
Differential growth sensitivity to 4-cis-hydroxy-L-proline of transformed rodent cell lines. (1988) (13)
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. (2015) (13)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) (2018) (12)
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. (1998) (12)
Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas (2020) (12)
Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC). (2014) (12)
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. (2002) (12)
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities (2021) (12)
Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification (2020) (11)
Overexpression of the RIα subunit of Protein Kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-Chloro-cyclic Adenosine 3′,5′-Monophosphate in chinese hamster ovary cells. (1994) (11)
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. (2021) (11)
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial (2019) (11)
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. (2019) (11)
254OACTIVITY OF NEOADJUVANT LAPATINIB (L) PLUS TRASTUZUMAB (T) FOR EARLY BREAST CANCER (EBC) ACCORDING TO PIK3CA MUTATIONS: PATHOLOGICAL COMPLETE RESPONSE (PCR) RATE IN THE CHERLOB STUDY AND POOLED ANALYSIS OF RANDOMIZED TRIALS. (2014) (11)
Nutritional Support in Lung Cancer Patients: The State of the Art. (2020) (11)
Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment (2017) (11)
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. (2021) (11)
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center. (2020) (11)
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment. (2017) (10)
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer (2021) (10)
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis (2020) (10)
Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. (2013) (10)
Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study (2021) (10)
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations (2016) (10)
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study (2020) (10)
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. (2014) (10)
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. (2016) (10)
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer (2019) (10)
Molecular alterations in basal cell carcinoma subtypes (2021) (10)
Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer (2005) (9)
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. (2017) (9)
Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study. (2021) (9)
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study (2018) (9)
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. (2019) (9)
Emerging Immunotargets in Bladder Cancer. (2016) (9)
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome (2020) (9)
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo (2020) (9)
Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview. (2021) (9)
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. (2015) (9)
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. (2018) (8)
Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases (2017) (8)
Present and future of personalized medicine in adult genitourinary tumors. (2015) (8)
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. (2019) (8)
Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. (2003) (8)
Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma (2020) (8)
Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents (2014) (8)
8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells. (1996) (8)
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. (2015) (8)
A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. (2019) (8)
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. (2021) (8)
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. (2017) (8)
Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. (2016) (8)
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. (2000) (7)
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. (2022) (7)
Antitumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. (2006) (7)
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. (2021) (7)
Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer (2018) (7)
MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO) (2017) (7)
The tyrosine kinase inhibitor ZD 6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells (2010) (7)
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma (2017) (7)
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine (2013) (7)
Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study (2019) (7)
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer (2015) (7)
Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? (2017) (7)
Biomarkers of response to advanced prostate cancer therapy (2020) (7)
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. (2019) (7)
Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers (2022) (6)
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study (2021) (6)
Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. (2006) (6)
Paraneoplastic Sensitive Neuropathy Associated with Anti-Hu Antibodies in a Neuroendocrine Tumor of Duodenum: A Case Report (2010) (6)
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives. (2014) (6)
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature (2021) (6)
Topical Vitamin E Acetate for the Treatment of Cheilitis: A Multicentre Experience (2003) (6)
The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients’ Age: A Systematic Review and Meta-Analysis (2020) (6)
Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma (2021) (6)
Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide (2015) (6)
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’? (2016) (6)
Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. (2020) (6)
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer (2016) (6)
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. (1995) (6)
Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients (2021) (6)
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel. (2015) (6)
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours (2017) (6)
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy (2013) (5)
Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer (2016) (5)
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus (2016) (5)
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage ‘pure’ and ‘mixed’ lobular breast cancer (2016) (5)
Prognostic Factors Affecting Survival after Pulmonary Resection of Metastatic Renal Cell Carcinoma: A Multicenter Experience (2021) (5)
Clinical meta-analyses of targeted therapies in adenocarcinoma (2013) (5)
Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers. (2016) (5)
Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma (2021) (5)
The effect of a treatment delay on outcome in metastatic renal cell carcinoma. (2019) (5)
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation (2018) (5)
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? (2018) (5)
Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day (2022) (5)
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. (2017) (5)
High-dose recombinant interleukin-2/verapamil combination in advanced cancer. (1996) (5)
892PTreatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP) (2017) (5)
Zd1839 (Iressa™): Preclinical Studies and Pharmacology (2002) (5)
The prognostic value of pain in castration-sensitive prostate cancer (2020) (5)
Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer 1 (2002) (5)
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. (2018) (5)
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study (2021) (5)
Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. (2019) (5)
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma (2013) (5)
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study (2022) (4)
Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. (2011) (4)
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model (2020) (4)
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. (2022) (4)
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms (2017) (4)
The role of precision medicine for the treatment of metastatic renal cell carcinoma (2016) (4)
O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study (2021) (4)
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma (2014) (4)
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers. (2022) (4)
Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection (2021) (4)
Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits. (1996) (4)
Clinical results of randomized trials and ‘real-world’ data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research (2017) (4)
Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR? (2016) (4)
Management of single pulmonary metastases from colorectal cancer: State of the art (2022) (4)
Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector (2004) (4)
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives (2022) (4)
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? (2022) (4)
Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents (2022) (4)
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. (2015) (4)
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. (2007) (4)
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era? (2020) (4)
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active? (2022) (4)
Prognostic Factors in Human Colorectal Cancer (1997) (4)
Development of a Digital Research Assistant for the Management of Patients’ Enrollment in Oncology Clinical Trials within a Research Hospital (2021) (4)
De Novo, Progressed, and Neglected Metastatic Castration‐Sensitive Prostate Cancer: Is One Therapy Fit for All? (2018) (4)
Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis (2021) (4)
OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC) (2017) (4)
Challenges in Crohn’s Disease Management after Gastrointestinal Cancer Diagnosis (2021) (4)
Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity (2003) (4)
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer. (2016) (4)
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors. (2019) (4)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
Advances in Brief Helicobacter pylori VacA Toxin UpRegulates Vascular Endothelial Growth Factor Expression in MKN 28 Gastric Cells through an Epidermal Growth Factor Receptor-, Cyclooxygenase-2-dependent Mechanism 1 (2003) (3)
Found in translation: annals of oncology and translational research. (2011) (3)
Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma. (2019) (3)
Poor efficacy of palbociclib in second‐line treatment of metastatic lobular breast cancer in a case series: Use before or never more? (2019) (3)
Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. (2021) (3)
Effects of mutant p53 genes on transformation of human mammary epithelial-cells. (1994) (3)
The role of bevacizumab in breast cancer (2008) (3)
HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. (2013) (3)
Homologous Repair Deficiency Status and Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: The Best Current Biomarker to Select the Most Appropriate Treatment? (2021) (3)
Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice. (2012) (3)
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. (2021) (3)
Dose-response of X-irradiated human and equine lymphocytes. (1997) (3)
Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach? (2020) (3)
Cooperative inhibition of human renal cancer cell growth by treatment with anti-epidermal growth factor receptor monoclonal antibody and a mixed backbone antisense oligonucleotide targeting type I protein kinase A (1998) (3)
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer (2021) (3)
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). (2022) (3)
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. (2019) (3)
Protein-kinase A and human disease: The core of cAMP-dependent signaling in health and disease (2002) (3)
Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors (2017) (3)
E15Effectiveness of Cetuximab (Cet) and Bevacizumab (Bev) for metastatic colorectal cancer (mCRC) according to primary tumor location (PTL): findings from a ‘real-world’ retrospective analysis (2015) (3)
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series † (2020) (3)
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study) (2021) (3)
Sorafenib for lung cancer: is the “Battle” still open? (2012) (3)
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy (2022) (3)
“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management (2021) (3)
Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. (2019) (3)
Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study (2022) (3)
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect (2003) (3)
Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response (2021) (3)
Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium (2021) (2)
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. (2016) (2)
Exploring the molecular and biological background of lung neuroendocrine tumours. (2019) (2)
Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC) (2016) (2)
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. (2017) (2)
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma (2018) (2)
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making (2022) (2)
C18Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC) (2016) (2)
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma (2021) (2)
Double tracer PET/CT: what is it and what does it mean? (2016) (2)
Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma. (2019) (2)
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial (2022) (2)
The Rationale for the Combination of Selective EGFR Inhibitors with Cytotoxic Drugs and Radiotherapy (2007) (2)
Abstract 3339: Modulating TAK1 expression through the inhibition of GSK3 impairs YAP/TAZ oncogenic functions in pancreatic cancer (2018) (2)
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies (2022) (2)
Overexpression of the RI alpha subunit of protein kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-chloro-cyclic adenosine 3'5'-monophosphate in Chinese hamster ovary cells. (1994) (2)
VEGF Receptor 1 contributes to resistance to anti-EGFR drugs in human cancer cells. (2008) (2)
Prospective trial in early-stage breast cancer (EBC) patients (pts) submitted to nutrition evidence-based educational intervention: Early results of adherence to dietary guidelines (ADG) and body weight change (BWC). (2019) (2)
Oral Anticancer Therapy Project: Clinical utility of a specific home care nursing program. (2016) (2)
Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells (2008) (2)
[Rationales for the integration of molecular and conventional therapies]. (2002) (2)
Mitoxantrone, Etoposide and bleomycin (meb) chemotherapy in non-hodgkins-lymphoma patients non-elegible for standard cyclophosphamide, Doxorubicin, vincristine and prednisone (chop) combination. (1995) (2)
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) (2021) (2)
Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC). (2017) (2)
Could a biomarkers-based patients' selection help to plan a clinical trial with targeted agents (TA) for metastatic renal cell carcinoma (mRCC)? Interaction and power analysis of randomized trials (RCTs). (2013) (2)
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. (2022) (2)
Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. (2020) (2)
Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody (2022) (2)
Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors: A Phase I Study (2006) (2)
179P Prognostic impact of body composition (BC) changes during neoadjuvant chemotherapy (NACT) in breast cancer patients (pts) (2020) (1)
EGFR-Directed Monoclonal Antibodies (2010) (1)
Upfront FOLFOXIRI Plus Bevacizumab with or Without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (ATEZOTRIBE): A Multicentre, Open-Label, Phase 2, Randomised Controlled Trial by GONO (2022) (1)
Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: A clinical-biological risk stratification model. (2012) (1)
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report (2015) (1)
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report. (2021) (1)
Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care (2007) (1)
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer (2022) (1)
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study (2020) (1)
Activity of nab-paclitaxel (nab-P) monotherapy in heavily pretreated pancreatic cancer (aPDAC) patients (pts): A multicenter retrospective analysis. (2013) (1)
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC). (2017) (1)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (2023) (1)
696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP) (2021) (1)
1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial (2020) (1)
Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model. (2018) (1)
Inside the 2015 ASCO Genitourinary Cancers Symposium. (2015) (1)
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics (2022) (1)
Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies. (2019) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Acquired hemophagocytic syndrome: comment to the case report (2015) (1)
POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMEA approval. (2013) (1)
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures (2021) (1)
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches (2022) (1)
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. (2022) (1)
Epidermal growth factor-related growth factors in human colorectal cancer (1995) (1)
Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study). (2019) (1)
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration (2002) (1)
P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study (2021) (1)
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma (2012) (1)
SO-3 Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial (2020) (1)
Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine. (2018) (1)
First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients. (2016) (1)
Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC). (2018) (1)
NUTRITIONAL DERANGEMENTS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS: PREVALENCE AND IMPACT ON TREATMENT OUTCOME (2020) (1)
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. (2022) (1)
Docetaxel in adjuvant therapy of breast cancer : results of the TAXIT 216 multicenter phase III trial ” (2008) (1)
1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer (2021) (1)
Overexpression of wild-type p53 overrides the mitogenic effect of ri-alpha subunit of protein-kinase-a in human breast cells. (1995) (1)
Safety and Feasibility of Analgosedation for Electrochemotherapy of Liver Lesions (2023) (1)
A Novel ATM Pathogenic Variant in an Italian Woman with Gallbladder Cancer (2021) (1)
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts (2007) (1)
POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). (2020) (1)
690PCLINICAL IMPACT OF FOLFIRINOX DOSE/SCHEDULE MODIFICATIONS (MFOLFORINOX) AND ADDITIONAL SUPPORTIVE MEASURES IN THE MANAGEMENT OF PANCREATIC CANCER (PDAC) PATIENTS (PTS). (2014) (1)
Differential effects of type I and type II protein kinase A isoforms on chinese hamster ovary cell cycle and proliferation. (1994) (1)
An antisense oligodeoxynucleotide targeted against the type I 1 p regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects ( cAMP kinase / regulatory-subunit antisense ) (1)
First-Line Treatment with Folfirinox in Advanced, Inoperable Pancreatic Cancer (APDAC) Patients (PTS): Supportive Measures Optimization for a Safe Administration in Routine Clinical Practice (2012) (1)
Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial. (2020) (1)
Protein Kinases as Targets for Cancer Therapy (2004) (1)
Oral administration of chimeric MBO antisense-protein kinase A inhibits growth, angiogenesis and growth factors production and cooperates with cytotoxic drugs in human cancer xenografts (1999) (1)
PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT). (2012) (1)
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models. (2018) (1)
POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC) (2019) (1)
Cardiovascular monitoring of drug-resistant lymphoma patients treated with epoch chemotherapy plus high-dose verapamil in continuous-infusion. (1994) (1)
Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P). (2020) (1)
Resistance to ALK Inhibitors (2016) (1)
Endocannabinoids as emerging suppressors of angiogenesis and breast tumor growth and metastatic spreading ” (2008) (1)
Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference. (2021) (1)
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer (2023) (1)
Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center (2022) (1)
Control of breast cancer cell growth by adipocyte-released factors ” (2009) (1)
Kidney cancer and 2014: is innovation really over? (2015) (1)
TGF-β-Activated Kinase 1 (TAK1) Is an In Vivo Druggable Target for Reverting Pancreatic Cancer Chemoresistance (2013) (1)
Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy (2007) (1)
Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis of a multicenter ‘real-world’ patients (pts) series (2019) (1)
High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs (2014) (1)
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma (2021) (0)
Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts) (2019) (0)
New genes involved in the neoplastic transformation of the thyroid gland (2006) (0)
Signaling Pathways, Mechanisms of Resistance and Treatment Decisions in Renal Cell Cancer (2012) (0)
165. Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia (AML) patients by site-selective 8-chloro-cyclic adenosine 3′, 5′ monophasphate (8-CI-cAMP): a new approach for differentiation therapy of AML in humans (1992) (0)
Tumor seeding after percutaneous US-guided FNA of solid pancreatic neoplasms (2016) (0)
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) (2022) (0)
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? (2016) (0)
PARP-1 involvement in growth inhibitory effects of temozolomide and topotecan in p53 wild-type (D54) and p53 mutated (U251) glioblastoma cells (2003) (0)
Histogram analysis of ADC maps: assessment of intra-tumoral heterogeneity and correlation with the biological behavior of pancreatic neuroendocrine neoplasms (2017) (0)
A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants (2022) (0)
Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon (2016) (0)
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? (2016) (0)
Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study (2014) (0)
1311PNEXT GENERATION SEQUENCING (NGS) REVEALS QUALITATIVE AND QUANTITATIVE MOLECULAR HETEROGENEITY WITHIN EGFR-MUTANT ADVANCED LUNG ADENOCARCINOMA (ALA) PATIENTS (PTS) RECEIVING GEFITINIB (G). (2014) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Abstract 3605: Combined inhibition of IL-1, CXCR1/2, and TGFβ signaling pathways modulates in vivo acquired resistance to anti-VEGF treatment (2015) (0)
Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study). (2019) (0)
Gene expression profile analysis of pituitary adenomas developed by HMGA transgenic mice ” (2007) (0)
An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study. (2022) (0)
Core curriculum oncologia clinica (2011) (0)
Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience (2014) (0)
DNA damage repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study. (2022) (0)
The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer (2006) (0)
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells (2003) (0)
Abstract 615: Novel Toll-like Receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancers (2010) (0)
ADHERENCE TO DIETARY GUIDELINES AND WEIGHT CHANGE IN BREAST CANCER PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE TRIAL (2020) (0)
P35.14 NGS-Based Molecular Profiling of ‘Quadruple-Negative’ (EGFR/KRAS/ALK/ROS1) Advanced Non-Small-Cell Lung Cancer (aNSCLC). (2021) (0)
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer (2009) (0)
Biological and clinical relevance of proliferative activity in inflammatory breast-cancer. (1995) (0)
Abstract 5401: The mTOR inhibitor everolimus cooperates with the Toll-like receptor 9 (TLR9) agonist IMO in renal cell carcinoma by interfering with both tumor cells and microenvironment (2010) (0)
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts (2005) (0)
Oral antisense targeting protein kinase A type I causes antitumor and apoptotic effect in human cancer cells in vitro and in vivo and has cooperative activity in combination with antisense bcl-2. (1999) (0)
2015 and human cancer: back to overall survival. (2016) (0)
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study. (2023) (0)
2-weekly docetaxel: issues for clinical practice (2015) (0)
An IT Platform Supporting Rectal Cancer Tumor Board Activities: Implementation Process and Impact Analysis (2022) (0)
Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario. (2023) (0)
Combination of biological therapies in non-small cell lung cancer. (2006) (0)
A15Development of a risk model to identity prognostic ‘outliers’ underwent surgery for early-stage invasive lobular breast carcinoma (ILBC) according to clinical and pathological factors (2015) (0)
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma (2018) (0)
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside (2013) (0)
1856P Clinical relevance of pancreatic enzyme replacement therapy (PERT) in patients affected by advanced pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy (2020) (0)
P-166 Baseline radiomics features in metastatic colorectal cancer: Correlation with metastatic site and clinical-pathological characteristics (2020) (0)
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study). (2018) (0)
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
A13Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model (2016) (0)
Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC). (2016) (0)
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis (2023) (0)
The Role of the Oncologist in the Diagnosis and Management of Malignant Cystic Neoplasms (2013) (0)
L11Prognostic impact of weight loss variation and nutritional parameters in patients affected by locally advanced or metastatic Head Neck Cancer (HNC) (2016) (0)
Related articles (2014) (0)
Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer. (2021) (0)
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
Prognostic Impact of Cytoskeleton Regulatory Protein Human Mena (hmena) Isoforms In Resected, Node-negative, Non-smallcell Lung Cancer: Validation of A Clinic-molecular Prognostic Model (2013) (0)
How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients. (2013) (0)
Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients: A Real-World Analysis (2022) (0)
820PLOSS OF CHROMOSOMES 9P AND 14Q: RE-PROFILING METASTATIC TISSUE FOR RE-TARGETING PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. (2014) (0)
Transcriptomic dissection of Intraepithelial Papillary Mucinous Neoplasms progression by spatial technologies identified novel markers of pancreatic carcinogenesis (2022) (0)
Type I Isoform of PKA is Involved in the Control of Cell Proliferation and Oncogene Transformation of Human Mammary Epithelial Cells: Therapeutic Implications (1993) (0)
ESGAR 2016 Book of Abstracts (2016) (0)
Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC). (2019) (0)
Baseline radiomics features (RF) in metastatic colorectal cancer (mCRC): Correlation with m site and clinical-pathological characteristics. (2020) (0)
248 Fibroblast Growth Factor Receptor (FGFR)3 sustains acquired resistance to trastuzumab in gastric cancer patients (2015) (0)
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer (2022) (0)
MA 01.07 Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 trial (2017) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Rare Secondary Tumors of the Pancreas (2013) (0)
Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study. (2016) (0)
N22Quality of care, patient needs and health-care profile in cancer inpatients: prospective observational clinical trial (2015) (0)
Phase I-II study of sequential combination of XELOX and bevacizumab plus erlotinib (XELOX-TARAV) in first line colorectal patients:Run in phase I part (2008) (0)
Efficacy of third-line anti-EGFR-based treatment (tx) versus (vs) Regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts). (2020) (0)
1000 A novel drug Toll-like receptor 9 (TLR9) agonist synergizes with trastuzumab in different trastuzumab-resistant breast tumours via multiple mechanisms of action (2009) (0)
The prognostic value of pain in castration-sensitive prostate cancer (2020) (0)
Abstract P2-02-06: Adjuvant Denosumab treatment in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials (2023) (0)
Prognostic Impact of the FHIT, APC and Human Epidermal Growth Factor-2 Receptor Overexpression in Resected Gastric Cancer: a Clinical Biological Risk Stratification Model. (2013) (0)
Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer (1999) (0)
Prognostic role of early nutritional support in patients affected by advanced pancreatic cancer undergoing chemotherapy (2018) (0)
640PMOLECULAR PORTRAIT OF RESECTED GASTRIC CANCER (RGC) WITH NEXT GENERATION SEQUENCING (NGS) ACCORDING TO A CLINICAL BIOLOGICAL RISK MODEL CONSIDERING FHIT, APC AND HER-2 OVEREXPRESSION. (2014) (0)
Abstract 3501: Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling (2018) (0)
Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives (2022) (0)
Cooperative antitumor and antiangiogenic activity after oral administration of a novel taxane, an antisense targeting protein kinase A and the EGF receptor inhibitor Iressa (2001) (0)
Chapter 2 Profiling mTOR Pathway in Neuroendocrine Tumors (2019) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
M01The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors (2016) (0)
30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer (2020) (0)
Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors. (2014) (0)
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study (2023) (0)
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations. (2022) (0)
Somatostatin Analogues or Active Surveillance in Sporadic and MEN1 associated Non-functioning Pancreatic Neuroendocrine Tumors (2023) (0)
Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype (2013) (0)
The protein kinase C beta antagonist enzastaurin (LY317615.HCl) inhibits cancer cell growth by multiple mechanisms and is active in EGFR inhibitors-resistant cancer cells (2006) (0)
N04Appropriateness and cost analyses of anticancer treatments (at) in the last 3 months of life: a retrospective single center cohort study (2015) (0)
MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer (2021) (0)
Chemotherapy Rechallenge or Reintroduction, Regorafenib and Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A PROpensity ScorE Analysis of Treatment Beyond Second Line (PROSERpYNa Study) (2023) (0)
Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC). (2016) (0)
Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial. (2020) (0)
Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials. (2012) (0)
Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer. (2018) (0)
Human cancer cell lines resistant to EGFR inhibitors acquire an altered expression of VEGFR-1/Flt-1 and become sensitive to ZD6474 (2006) (0)
Adjuvant therapy (AT) in patients (pts) with radically resected ampullary adenocarcinoma (AA): A monocentric retrospective analysis. (2022) (0)
Molecular mechanisms of insulin resistance : role of endocannabinoid system in the regulation of glucose metabolism and insulin action ” (2007) (0)
Definition of a tool to assess shared decision‐making (SDM) on women with breast cancer: A value‐based approach (2022) (0)
Molecular Markers in the Prediction of Response to Neoadjuvant Treatments in Esophagogastric Junction Adenocarcinoma (2017) (0)
The impact of 2nd-line treatment (tx) after 1st-line Gemcitabine plus Nab-paclitaxel (GemNab) in advanced pancreatic cancer (APC) patients (pts). (2020) (0)
Colorectal cancer lung metastasis: Could multidisciplinary management suggest the right strategy? (2019) (0)
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models. (2012) (0)
Efficacy of VEGFR-TKI plus immune checkpoint inhibitor (ICI) in metastatic renal cell carcinoma (mRCC) patients with favorable IMDC prognosis. (2021) (0)
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial (2019) (0)
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer (2020) (0)
7164 POSTER Adjuvant Treatment for Resected Renal Cell Carcinoma (RCC): Are All Strategies Equally Negative? Meta-analysis of Randomized Trials (RCTs) (2011) (0)
The impact of a multidisciplinary approach (MA) in the management of pancreatic disease (PD). (2020) (0)
Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis. (2019) (0)
1309 POSTER How Much is the Likelihood of Being Helped or Harmed (LHH) When Adopting Oral Targeted Agents (OTA) in the Treatment of Advanced Solid Tumours (AST) – Comprehensive Assessment of Their Clinical Overall Impact According to FDA/EMEa Regulatory Approvals (2011) (0)
Immune Profile Of Uveal Melanoma Patients: Impact On Clinical Outcome (2021) (0)
P2.04-12 A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC. (2018) (0)
TAILORED NUTRITIONAL SUPPORT AS A PREDICTIVE FACTOR FOR SURVIVAL IN HEAD AND NECK CANCER PATIENTS UNDERGOING TREATMENTS (2019) (0)
Gefitinib and Radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck ” (2008) (0)
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients (2023) (0)
Propensity score analysis investigating the role of hormonal maintenance (HM) for advanced breast carcinoma with luminal subtype (ABC-Lum): Implication for prognostic modeling, post-progression and conditional survival (PPS/CS). (2016) (0)
P-102 The impact of a multidisciplinary approach in the management of pancreatic disease (2020) (0)
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) (2007) (0)
Cancer Therapy : Preclinical Toll-like Receptor 9 Agonist IMOCooperateswithCetuximab in KRas Mutant Colorectal and Pancreatic Cancers (2011) (0)
A Treatment-Interaction Analysis Balancing Pathological Complete Responses (PCR) and Cardiotoxicity of Single-(S)/Dual-(D) HER2 Inhibition and Neoadjuvant Chemotherapy (CT) Backbone in Operable/Locally Advanced Breast Cancer (O/LABC) Patients (2012) (0)
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy (2015) (0)
377POVERALL PROGNOSIS OF ADVANCED BREAST CANCER (ABC) ACCORDING TO CHEMOTHERAPY (CT) TREATMENT LINES: CORRELATION ANALYSIS BETWEEN PROGRESSION-FREE-, POST-PROGRESSION- AND OVERALL- SURVIVAL (PFS, PPS AND OS). (2014) (0)
PO-138 Prognostic value of tailored nutritional support in Head and Neck cancer patients undergoing treatments (2019) (0)
A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC). (2018) (0)
Abstract 26: Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001 (2016) (0)
P1.16-43 Prevalence of Clinical and Sub-Clinical Malnutrition in Advanced Non-Small-Cell Lung Cancer Patients and Association with Outcome (2019) (0)
“Targeting” renal cell carcinoma patients with “targeted” agents: Are we there yet? (2014) (0)
Site-selective cyclic AMP (cAMP) analogs provide a new approach in the control of breast and colon cancer growth (1987) (0)
F38Autophagy and transplantation: organ injury and cancerogenesis by molecular expression of LC3B (2015) (0)
P-164 The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel (2020) (0)
Nutritional Interventions during Chemotherapy for Pancreatic Cancer: A Systematic Review of Prospective Studies (2023) (0)
BRIEF REPORTS Flow-Cytometric Detection of the RIa Subunit of Type I CAMP-Dependent Protein Kinase in Human Cells (2004) (0)
New biomolecular prognostic and predictive factors of response to treatments in colorectal cancer ” (2010) (0)
F30New agents (nas) in metastatic castration-resistant prostate cancer (mcrpc): is there a sequence better than the others? (2015) (0)
Differential Growth Sensitivity to 4-as-HydroxyL-proline of Transformed Rodent Cell (2006) (0)
101PA circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma (2017) (0)
1093 A novel IL12-based immunocytokine targeting fibroblast activation protein (FAP) for the treatment of cancer (2022) (0)
PTEN loss as predictor of tumour heterogeneity (TH) and poor prognosis in EGFR-mutant advanced non-small cell lung cancer (ANSCLC) patients (pts) receiving tyrosine-kinase inhibitors (TKIs) (2019) (0)
Nab-paclitaxel (nab-p) in association with FOLFIRI (Nab-FOLFIRI) or FOLFOX (Nab-FOLFOX) for metastatic pancreatic cancer: A phase I/II trial by Italian Oncology Group for Clinical Research (GOIRC)—NabucCO Trial. (2015) (0)
P1.05-050 External Validation of a Prognostic Model for Squamous-Cell Lung Cancer and Impact of Adjuvant Treatment in >1,300 Patients: Topic: Neoadjuvant and Adjuvant Chemotherapy (2017) (0)
204PESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model (2017) (0)
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy (2023) (0)
Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors (2007) (0)
Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients (2023) (0)
Mechanisms of Resistance to ALK-inhibitor Agents (2015) (0)
F37De novo renal cell neoplasia after kidney transplantation, according to the International Society of Urological Pathology (ISUP 2013) Vancouver Classification (2015) (0)
Blockade of protein kinase A and BCL-2 by antisense strategy cooperatively inhibits human cancer growth and angiogenesis and induces apoptosis in nude mice (2000) (0)
Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis. (2019) (0)
Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients. (2019) (0)
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. (2023) (0)
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage ‘pure’ and ‘mixed’ lobular breast cancer (2016) (0)
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis (2020) (0)
OC.01.4 SAFETY AND EFFICACY OF EUS-GUIDED RADIOFREQUENCY ABLATION FOR PANCREATIC INSULINOMA: A SINGLE-CENTRE EXPERIENCE (2023) (0)
Abstract 579: TAK1-regulated expression of BIRC3 is responsible for chemoradiotherapy (CRT) resistance in esophagogastric junction (EGJ) adenocarcinoma (2015) (0)
Impact of pancreatic enzyme replacement therapy (PERT) on survival in patients affected by advanced pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy (2020) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma (2023) (0)
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial). (2022) (0)
The role of primary tumor (PT) site as prognostic factor after resection of colorectal (CRC) liver metastases (LM): A mono-institutional cohort study. (2020) (0)
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELO-TARAV) in first line colorectal cancer: Run in part. (2007) (0)
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 (2004) (0)
28 Synergistic antiproliferative effects of ionizing radiations with anti-epidermal growth factor receptor monoclonal antibody C225 and protein kinase a antisense oligonucleotide hyb 165 (1999) (0)
P-152 The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients (2020) (0)
Phase I clinical trial of high dose recombinant interleukin-2/veparimil combination in advancer cancer. (1996) (0)
10 OP Helicobacter pylori VacA cytotoxin stimulates the release of VEGF from human gastric epithelial cells in vitro through an EGF-receptor-mediated pathway (2002) (0)
Doctorate Program in Molecular Oncology and Endocrinology XVIII cycle-2002–2006 Coordinator: Prof. Giancarlo Vecchio “NOVEL MECHANISMS RESPONSIBLE FOR CONTROLLING GLUCOSE-INDUCED INSULIN SECRETION IN PANCREATIC BETA-CELLS” (2006) (0)
P1.01-69 Blood Serum Amyloid A as Potential Predictor of Response to First-Line Pembrolizumab in Patients with Advanced Non-Small-Cell Lung Cancer (2019) (0)
P-103 The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study (2020) (0)
Maintenance strategies after anti–EGFR-based induction in RAS wild-type (wt) metastatic colorectal cancer (mCRC): A systematic review and Bayesian network meta-analysis. (2023) (0)
Actualities on Diagnosis, Targeting and Treating Bone Metastases in Breast Cancer with Radiotherapy and New Drugs (2020) (0)
Prognostic value of ALK gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts). (2014) (0)
1640PPI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC) (2017) (0)
B07An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (nab®-paclitaxel) + Gemcitabine vs Gemcibatine alone for Metastatic Pancreatic Cancer Patients: The APICE Study (2016) (0)
F11Prognostic impact of Ki67 for resected early stage pure Invasive Lobular breast Cancer (ILC): cut-off analysis and clinical validation (2016) (0)
Abstract 616: R1507, the human monoclonal antibody targeting the insulin-like growth factor receptor (IGF-1R), in combination with cetuximab, can reverse acquired resistance to cetuximab in pancreatic and colon cancer models (2010) (0)
Molecular answers and targets on the horizon for the treatment of genitourinary malignancies (2012) (0)
Nab-paclitaxel in substitution of oxaliplatin and irinotecan in folfirinox schedule as first-line therapy in patients with metastatic pancreatic cancer: results of phase I dose finding of NabucCO study by GOIRC (2016) (0)
The impact of first-line chemotherapy in elderly patients (pts) with advanced pancreatic cancer (APC): A mono-institutional retrospective study. (2021) (0)
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade (2016) (0)
Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies. (2019) (0)
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC). (2017) (0)
Has crizotinib significantly impacted non-small-cell lung cancer therapy? (2020) (0)
P-161 Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients (2020) (0)
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study (2014) (0)
Imaging of lung cancer resistance to EGFR tyrosine kinase inhibitors trough Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3 (2008) (0)
A02*Clinical and pathological predictors of Advanced Breast Carcinoma with Luminal subtype (ABC-Lum) identifying prognostic ‘outliers’: multicenter retrospective analysis in the ‘real-world’ scenario (2015) (0)
Abstract P1-19-43: Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis (2020) (0)
Related articles (2014) (0)
The role of site of metastatic resection (MR) in metastatic colorectal cancer (mCRC) patients (PTS): A mono-institutional cohort study. (2021) (0)
Angiogenic and Signalling Proteins Correlate Resistance and Sequence of Treatment in Renal Cell Cancer (2012) (0)
Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study). (2019) (0)
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study (2015) (0)
Neoplasie del colon retto (2010) (0)
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response (2023) (0)
Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer. (2022) (0)
RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model (2016) (0)
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analisys. (2021) (0)
1183PDRISK STRATIFICATION MODEL FOR RESECTED SQUAMOUS CELL LUNG CANCER (R-SQLC) PATIENTS (PTS) ACCORDING TO CLINICAL AND PATHOLOGICAL FACTORS. (2014) (0)
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer. (2016) (0)
A digital solution to support the Multidisciplinary Tumor Board activities: implementation process and impact analysis (2023) (0)
The role of response as predictor of improved outcome in advanced pancreatic cancer (APC) patients (pts) treated with first-line Gemcitabine plus Nab-paclitaxel (GemNab). (2020) (0)
Targeted and Other Non-receptor-mediated Therapies (2013) (0)
FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care. (2015) (0)
469P Potential emergent role of liquid biopsy in clinical practice in metastatic colorectal cancer (mCRC) treatment (2021) (0)
P-83 The impact of the multidisciplinary team (MDT) in the management of colorectal cancer (CRC) (2022) (0)
Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors (2016) (0)
Doctorate Program in Molecular Oncology and Endocrinology (2006) (0)
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer (2003) (0)
The role of autophagy in neoplastic cell response to oncolytic viruses ” (2009) (0)
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. (2004) (0)
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer (NSCLC) overexpressing PD-L1: Early results of the FoRECATT Study. (2020) (0)
Exploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study] (2019) (0)
285P Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis (2020) (0)
P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial (2019) (0)
The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study. (2022) (0)
H20Detection of EGFR alterations in circulating tumor DNA of non-small cell lung cancer by digital PCR and Next Generation Sequencing (2015) (0)
79. Over expression of protein kinase subunits differentially affects morphology, growth and differentiation of human and rodent epithelial cells (1992) (0)
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program (2022) (0)
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts (2005) (0)
SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study (2022) (0)
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis (2022) (0)
Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies. (2017) (0)
P-97 DNA damage repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study (2022) (0)
Adenosine 3′–5′ monophosphate (cAMP) reduces neointima formation and smooth muscle cell proliferation after balloon injury (1998) (0)
P-73 The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study (2021) (0)
234P CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety (2022) (0)
1592P Cardiovascular toxicity in patients treated with a PARP inhibitor for solid tumors: A meta-analysis (2022) (0)
Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC). (2018) (0)
1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer (2021) (0)
1298P Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation (2022) (0)
Role of Chemoradiation in the Adjuvant Treatment of Radically Resected Pancreatic Cancer Patients: A Mono-Institutional Retrospective Analysis (2022) (0)
P-148 The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study (2022) (0)
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial (2019) (0)
Immune profile of metastatic uveal melanoma during treatment with pembrolizumab. (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giampaolo Tortora?

Giampaolo Tortora is affiliated with the following schools:

Giampaolo Tortora's Academic­Influence.com Rankings

Giampaolo Tortora's Degrees

Similar Degrees You Can Earn

Why Is Giampaolo Tortora Influential?

Giampaolo Tortora's Published Works

Published Works

What Schools Are Affiliated With Giampaolo Tortora?

Giampaolo Tortora's AcademicInfluence.com Rankings